TL;DR
For each dimension where one drug clearly wins, we name the winner. When the answer is "depends on your situation," the verdict text below the table explains why.
| Dimension | What the data says | Winner |
|---|---|---|
| FDA-approved for | Diabetes (Mounjaro) vs weight loss + OSA (Zepbound) | Zepbound |
| Active ingredient | Both are tirzepatide | Tie |
| Maximum dose | Both 15mg weekly | Tie |
| Insurance coverage for weight loss | Zepbound with PA; Mounjaro rarely covered off-label | Zepbound |
| Cash channel for weight loss | LillyDirect handles Zepbound for cash-pay | Zepbound |
| Cost with diabetes diagnosis | Mounjaro $25-$50/mo with PA | Mounjaro |
Verdict
For weight loss patients without diabetes, Zepbound is the right answer. Same molecule as Mounjaro, same dose range, but FDA-approved for the indication you have, with a cash channel (LillyDirect) and insurance pathway purpose-built for weight loss. For patients with type 2 diabetes, Mounjaro is the indicated option and weight loss is a secondary benefit; insurance coverage is straightforward and the diabetes diagnosis is the gate.
Trial efficacy compared
The headline numbers are not from the same study, so direct comparison is approximate.
| Mounjaro | Zepbound | |
|---|---|---|
| Registration trial | SURPASS-2 (NEJM, 2021) | SURMOUNT-1 (NEJM, 2022) |
| Duration | 40 weeks | 72 weeks |
| Mean weight loss (max dose) | 13.1% | 20.9% |
| Effect vs comparator | 6.4 pp vs semaglutide 1mg | 17.8 pp vs placebo |
| Patients losing ≥5% | 86% | 91% |
| Patients losing ≥15% | 40% | 56.7% |
2026 cash-pay cost compared
LillyDirect for Zepbound is the direct cash channel that runs well below the retail pharmacy cash price; the other has no public manufacturer cash-pay channel for weight loss. Telehealth programs add a membership fee on top of medication cost.
| Channel | Mounjaro | Zepbound |
|---|---|---|
| Retail cash | $1,069/mo | $1,099/mo |
| Manufacturer DTC | Not publicly available for cash-pay; LillyDirect handles Zepbound for weight loss | $299-$449/mo via LillyDirect (vials) |
| With insurance + PA | $25-$50/mo with diabetes diagnosis and prior authorization | $25-$50/mo with prior authorization |
| Compounded | $199-$349/mo via 503A pharmacies (same active ingredient as Zepbound) | $175-$199/mo via 503A pharmacies (regulatory exposure; Strut $99 is an oral lozenge) |
When to choose Mounjaro
Choose Mounjaro if: (1) you have type 2 diabetes (it is the indicated option); (2) your insurance covers Mounjaro but not Zepbound on its formulary; (3) you are using a telehealth program that has stronger relationships with Lilly's diabetes channel than the weight loss channel.
When to choose Zepbound
Choose Zepbound if: (1) you do not have diabetes and want tirzepatide for weight loss (Zepbound is the indicated option, Mounjaro is off-label); (2) you want access to LillyDirect's cash-pay channel for self-pay patients; (3) you want the cleanest insurance prior authorization pathway. Zepbound's PA approval criteria for obesity are well-documented; off-label Mounjaro for weight loss is rarely covered post-2024.
Programs that prescribe each
Some visit links earn us a commission.
Top Mounjaro programs
Top Zepbound programs
FAQ
Are Mounjaro and Zepbound the same drug?
Why was Mounjaro prescribed off-label for weight loss before Zepbound launched?
Can a telehealth program prescribe both?
Is one of them safer?
Read the full drug profiles
Editorial disclosure
GLP Chart is an editorial comparison site. We do not dispense, prescribe or fulfill medications. Trial data is from the cited NEJM publications. Pricing reflects publicly verified rates as of June 22. Talk to a licensed clinician about which medication is appropriate for you.
